Menu
Recruiting NCT07653295

Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System

Observational Revision Hip Arthroplasty Aseptic Loosening of Prosthetic Joint Prostheses-related Infections Joint Instability

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tıpmed™ Revision Hip Prosthesis System.
Who it may be relevant to
Registry conditions: Revision Hip Arthroplasty, Aseptic Loosening of Prosthetic Joint, Prostheses-related Infections, Joint Instability. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System

Overview

This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Revision Hip Prosthesis System in adult participants undergoing revision hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.

Detailed description

This prospective, multi-center, observational, Post-Market Clinical Follow-Up (PMCF) study evaluates the short-to-medium-term safety and efficacy data of the Tipmed™ Revision Hip Prosthesis System in adult patients undergoing revision hip arthroplasty (total or partial) across participating clinical centers in Turkey. A total of 35 eligible participants will be enrolled in accordance with the pre-defined inclusion and exclusion criteria. Pre-operative demographic details, comprehensive medical history, previous arthroplasty data, and specific indications for revision surgery (such as aseptic loosening, infection, dislocation, or periprosthetic fractures) will be captured retrospectively from patient medical charts. Following the baseline revision surgical procedure, subjects will undergo a 24-month clinical follow-up period consisting of 6 routine post-operative assessment windows: at 6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months. At each longitudinal visit, investigators will complete a study-specific Case Report Form (CRF) to document objective clinical and survival indicators. Clinical performance and joint functionality profiles will be quantitatively monitored utilizing the Harris Hip Score (HHS). Safety endpoints will be continuously evaluated by identifying, classifying, and reporting any adverse events (AEs), serious adverse events (SAEs), implant-related complications (including re-revision rates, dislocation, aseptic loosening, infection, or nerve/vascular injuries), and hardware deficiencies. Radiological findings (implant positioning, component orientation, migration, osteointegration, and status of acetabular/femoral bone loss) and laboratory indicators (such as C-Reactive Protein and Sedimentation Rate) will be documented when available as part of standard medical surveillance.

Demographic characteristics, baseline clinical parameters, and longitudinal efficacy/safety outcomes will be summarized using descriptive statistics. Stratified analyses will be conducted based on the specific type of revision surgical intervention. Separate subgroup analyses will be executed for study participants who undergo partial revision hip arthroplasty to isolate and evaluate their clinical outcomes independently from the patients treated with total revision hip arthroplasty. Categorical variables across these subgroups will be compared using the Chi-square test or Fisher's exact test, as appropriate.

Interventions

  • Device Tıpmed™ Revision Hip Prosthesis System
    Post-market evaluation of the commercially available, CE-marked Tıpmed™ Revision Hip Prosthesis System during routine revision orthopedic care. Surgeon-directed device configurations are utilized based on patient-specific bone loss and anatomy, incorporating various mono-block or modular femoral stems, modular femoral body components, and femoral necks. Acetabular reconstruction elements encompass various configurations including acetabular cups, bipolar cups, and titanium metal shells with modu

Primary outcome measures

  • Functional Joint Performance via Harris Hip Score (HHS) at 24 Months [Time frame: 24 months post-operatively]
  • Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time frame: From the signing of informed consent up to 24 months post-operatively.]
  • Incidence of Clinical Complications [Time frame: From the time of signing the informed consent form up to 24 months post-operatively.]
Secondary outcome measures (1)
  • Longitudinal Changes in Hip Functioning via Harris Hip Score (HHS) [Time frame: Retrospective pre-operative baseline, and prospective assessments at 6 weeks, 3, 6, 12, 18, and 24 months post-operatively.]

Eligibility criteria

Inclusion criteria

  • Individuals aged 18 years and older,
  • Male or female participants,
  • Participants who have undergone Revision Hip Arthroplasty (either total revision or partial component revision) for any indication (such as a documented joint failure or prosthesis-related clinical complication),
  • Participants in whose revision procedure the Tıpmed™ Revision Hip Prosthesis System components were utilized,
  • Participants who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship),
  • Participants who have voluntarily signed the written Informed Consent Form (ICF).

Exclusion criteria

  • Subjects currently participating in any other interventional clinical trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Turkey (Türkiye) · 4 centers
  • Republic of Turkey Ministry of Health, Balıkesir Provincial Health Directorate, Atatürk Ci — Balıkesir
  • Republic of Turkey Ministry of Health, Balıkesir Provincial Health Directorate, Burhaniye — Balıkesir
  • Dokuz Eylül University Research and Application Hospital — Izmir
  • Republic of Turkey Ministry of Health Izmir Provincial Health Directorate Izmir Democracy — Izmir

Identifiers

NCT: NCT07653295 · INFO TPMHIP R · 2023-191

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗